Wheatgrass inhibits the lipopolysaccharide-stimulated inflammatory effect in RAW 264.7 macrophages.
Anti-inflammatory effect
COX-2
Lipopolysaccharide
RAW 264.7 cells
Wheatgrass
iNOS-2
Journal
Current research in toxicology
ISSN: 2666-027X
Titre abrégé: Curr Res Toxicol
Pays: Netherlands
ID NLM: 101771915
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
12
2020
revised:
11
02
2021
accepted:
18
02
2021
entrez:
4
8
2021
pubmed:
5
8
2021
medline:
5
8
2021
Statut:
epublish
Résumé
Inflammation is a multifaceted set of cellular communications generated against foreign infection, toxic influence or autoimmune injury. The present study investigates the anti-inflammatory effect of wheatgrass extract against the harmful impact of lipopolysaccharide (LPS) in macrophage cells, i.e., RAW 264.7 cells. Our results indicate that 5- and 7- days old wheatgrass extracts inhibit the LPS-stimulated production of nitric oxide. Moreover, wheatgrass extract significantly downregulates the mRNA expression of LPS-stimulated various pro-inflammatory markers, tumor necrosis factor-α, interleukin-6, interleukin-1β, AP-1 and also iNOS-2 and COX-2. Our flow cytometry analyses confirmed that wheatgrass extract prevents the generation of reactive oxygen species in LPS-stimulated RAW 264.7 cells, thus arresting oxidative stress in cells. The immunoblot analyses also confirmed a significant reduction in the expression of inflammatory proteins, namely, iNOS-2 and COX-2, in wheatgrass extract-treated cells, compared to LPS-stimulated condition. The NF-κB transactivation assay further confirmed the inhibitory effect of wheatgrass extracts on the LPS-stimulated expression of NF-κB. Molecular docking based studies showed the plausible binding of two significant wheatgrass constituents, i.e., apigenin and myo
Identifiants
pubmed: 34345856
doi: 10.1016/j.crtox.2021.02.005
pii: S2666-027X(21)00010-4
pmc: PMC8320646
doi:
Types de publication
Journal Article
Langues
eng
Pagination
116-127Informations de copyright
© 2021 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Exp Bot. 2009;60(6):1537-53
pubmed: 19386614
Trends Mol Med. 2007 Nov;13(11):460-9
pubmed: 18029230
Food Chem. 2019 Aug 1;288:256-261
pubmed: 30902290
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Autoimmun Rev. 2011 May;10(7):369-74
pubmed: 21195808
Semin Immunopathol. 2013 Mar;35(2):123-37
pubmed: 22996682
Nat Rev Cancer. 2006 Jul;6(7):521-34
pubmed: 16794635
J Nat Prod. 2020 Apr 24;83(4):1107-1117
pubmed: 32091204
Eur Heart J. 2012 Apr;33(7):829-37, 837a-837d
pubmed: 21890489
Int J Oncol. 2007 Jan;30(1):233-45
pubmed: 17143534
Eur J Pharmacol. 2020 Feb 5;868:172854
pubmed: 31837308
Nutrients. 2020 Sep 04;12(9):
pubmed: 32899726
Cells. 2019 Feb 22;8(2):
pubmed: 30813369
Wiley Interdiscip Rev Syst Biol Med. 2016 Jan-Feb;8(1):87-99
pubmed: 26459225
Int J Mol Sci. 2019 Mar 15;20(6):
pubmed: 30875872
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
Mini Rev Med Chem. 2015;15(12):1002-10
pubmed: 26156538
Commun Biol. 2020 Mar 18;3(1):132
pubmed: 32188886
Inflammopharmacology. 2007 Dec;15(6):252-9
pubmed: 18236016
Cell Immunol. 2013 Sep-Oct;285(1-2):49-54
pubmed: 24071564
J Ethnopharmacol. 2006 Jul 19;106(3):418-24
pubmed: 16530364
Redox Biol. 2020 Jul;34:101567
pubmed: 32464501
Circ J. 2011;75(12):2739-48
pubmed: 22067929
Redox Biol. 2020 Jul;34:101550
pubmed: 32438317
J Food Sci. 2018 Aug;83(8):2127-2139
pubmed: 30059150
Chem Res Toxicol. 2009 Aug;22(8):1376-85
pubmed: 19645497
J Food Sci Technol. 2021 Aug;58(8):3019-3029
pubmed: 34294964
Int J Cancer. 2007 Dec 1;121(11):2357-63
pubmed: 17893865
Nat Med. 2015 Jul;21(7):677-87
pubmed: 26121197
Br J Pharmacol. 2012 Mar;165(6):1926-1940
pubmed: 21913901
J Clin Diagn Res. 2017 Jun;11(6):ZC40-ZC42
pubmed: 28764290
J Am Coll Cardiol. 2017 Oct 31;70(18):2278-2289
pubmed: 29073957
Cancer Lett. 2014 Oct 10;353(1):1-7
pubmed: 25079686
Eur J Pharmacol. 2020 May 15;875:173035
pubmed: 32097657
NPJ Microgravity. 2020 Feb 24;6:6
pubmed: 32133389
Prog Neurobiol. 2006 Apr;78(6):347-63
pubmed: 16716487
Arthritis Rheum. 1998 Jul;41(7):1141-51
pubmed: 9663469
J Biochem Mol Toxicol. 2020 Feb;34(2):e22424
pubmed: 31743544
J Clin Periodontol. 2019 Apr;46(4):438-447
pubmed: 30629753
J Clin Pharm Ther. 2012 Feb;37(1):22-6
pubmed: 21204889
J Altern Complement Med. 2007 Oct;13(8):789-91
pubmed: 17983333
J Chem Inf Model. 2011 Oct 24;51(10):2778-86
pubmed: 21919503
Int Immunopharmacol. 2017 Aug;49:21-29
pubmed: 28550731
Toxicol Mech Methods. 2018 Mar;28(3):205-218
pubmed: 29160133
Free Radic Res. 2004 Nov;38(11):1241-53
pubmed: 15621702
Annu Rev Pharmacol Toxicol. 2012;52:199-219
pubmed: 21910626
Heliyon. 2020 Feb 19;6(2):e03436
pubmed: 32149199
Pharmaceuticals (Basel). 2020 Jun 23;13(6):
pubmed: 32585974
Cancer Lett. 2009 Feb 8;274(1):132-42
pubmed: 18952368
Cell Rep. 2020 Jun 30;31(13):107826
pubmed: 32610127
Int Immunopharmacol. 2011 Sep;11(9):1150-9
pubmed: 21443976
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
Cell Biosci. 2015 Nov 16;5:63
pubmed: 26579219
Inflammopharmacology. 2018 Dec;26(6):1359-1373
pubmed: 30229507
J Biol Chem. 2010 Nov 5;285(45):34950-9
pubmed: 20810665